For All Your Latest Medical News, Health News, COVID-19 News, H5N1 News, Long COVID News And News About The Thailand Medical Industry

Source: COVID-19 Drugs  Jul 10, 2020  3 years ago
WARNING! COVID-19 Drugs: Study Shows Elderly COVID Patients Have Increased Risks Of Bradycardia When Given Lopinavir and Ritonavir
WARNING! COVID-19 Drugs: Study Shows Elderly COVID Patients Have Increased Risks Of Bradycardia When Given Lopinavir and Ritonavir
Source: COVID-19 Drugs  Jul 10, 2020  3 years ago
COVID-19 Drugs: Despite numerous studies showing that Lopinavir and Ritonavir are not effective to treat COVID-19, we still have numerous ignorant countries and doctors still using those drugs in their treatment protocols.

Now a new French study shows that older, critically ill patients with COVID-19 who received a combination of the antiretroviral medications lopinavir and ritonavir experienced bradycardia, a slow heart rate, more often.
The research findings are published in the journal: Circulation: Arrhythmia and Electrophysiology, an American Heart Association journal.
The drug combo of antiretroviral medications lopinavir (LPV) and ritonavir (RTV) have been previously used to treat patients with SARS-Cov-1 and MERS-Cov, as well for HIV-1 patients. Among HIV-1 patients, a risk of bradycardia was also reported.
Significantly, in this small, preliminary, prospective study, researchers recorded the risk of bradycardia in critically ill COVID-19 patients treated with this combination of medications.
Typically, Bradycardia is classified as a heart rate below 60 beats per minute for a period of more than 24 hours. Bradycardia can cause problems if the slow heart rate leads to a decrease in blood flow to the body. This can lead to heart failure, fainting, chest pain and low blood pressure. In some people, bradycardia does not cause any symptoms.
The research study included 41 patients with COVID-19 admitted to the intensive care unit at Amiens University Hospital, in Amiens, France, who were treated with 200 mg LPV and 50 mg RTV twice daily for 10 days. All patients received continuous electrocardiogram (ECG) monitoring.
It was found that among the patients who received the LPV/RTV treatment:
-22% experienced bradycardia for more than 24 hours.
-bradycardia occurred at least 48 hours after initiation of treatment, indicating that the medications may have caused bradycardia.
-a blood test measuring the concentration of ritonavir (RTV plasma concentration) at 72 hours after receiving the treatment showed higher concentrations of RTV in the patients who had bradycardia.
-no correlation was found between RTV plasma concentration, LPV plasma concentration and mean heart rate at 3-days after LPV/RTV treatment began.

-patients experiencing bradycardia were on average older than patients receiving the treatment who did not experience bradycardia (ages 62-80 vs. 54-68, respectively).
-bradycardia resolved after LPV/RTV were discontinued or doses were reduced.
Corresponding author, Dr Christophe Beyls, Department of Anesthesiology and Critical Care Medicine, Amiens University Hospital, Amiens, France told Thailand Medical News, "LPV and RTV have complex pharmacokinetic characteristics ie how the body processes a medication . Bradycardia could be a sign of severe cardiological or neurological impairment since it is associated with lymphopenia  or lower than n ormal number of white blood cells that seems to reflect the severity of COVID-19 infection. Intensivists should be aware of this potential side effect in order to closely monitor LPV/RTV plasma levels, notably in elderly patients."
THE US CDC and even WHO, based on various clinical trials that have showed that Lopinavir and Ritonavir has no efficacy against SARS-Cov-2, have stopped recommending its use for treating COVID-19. Some primitive countries and doctors are still however using it in their protocols.
In one South-East Asian country where the authorities and healthcare professionals are claiming that it did a great job ‘stamping out’ the COVID-19 despite the fact that the country was lucky in that it had only the mild strains of the coronavirus going around and that it had nothing to do with the efficiency of its healthcare sector, even hilariously had its doctors and health officials announce that they had developed a treatment protocol using Lopinavir and Ritonavir along with Oseltamivir to treat COVID-19! The announcement was covered in many of the local media famous for fake news and misinformation.
For more on COVID-19 Drugs, keep on logging to Thailand Medical News.


Sep 25, 2022  8 months ago
Source: Medical News - SARS-CoV-2 Fall And Winter 2022 Variant Collections
Sep 08, 2022  9 months ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  10 months ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  3 years ago
Source: Supplements For COVID-19
Feb 05, 2020  3 years ago
Source : Thailand Medical news